PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/22867

Title:	PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
Authors:	Stern, Howard M Gardner, Humphrey Burzykowski, Tomasz Elatre, Wafaa O'Brien, Carol Lackner, Mark R Pestano, Gary A Santiago, Angela Villalobos, Ivonne Eiermann, Wolfgang Pienkowski, Tadeusz Martin, Miguel Robert, Nicholas Crown, John Nuciforo, Paolo Bee, Valerie Mackey, John Slamon, Dennis J Press, Michael F View more
Mesh:	Adult Aged Antineoplastic Agents Breast Neoplasms Drug Resistance, Neoplasm Female Humans Immunohistochemistry Kaplan-Meier Estimate Middle Aged PTEN Phosphohydrolase Proportional Hazards Models Receptor, ErbB-2 Tissue Array Analysis Trastuzumab View more
Issue Date:	1-May-2015
Citation:	Clin. Cancer Res..2015 May;(21)9:2065-74
Abstract:	To investigate the clinical relevance of PTEN in HER2-amplified and HER2-nonamplified disease.
PMID:	25649019
URI:	https://hdl.handle.net/20.500.12530/22867
Rights:	openAccess
ISSN:	1078-0432
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos

Files in This Item:

File	Description	Size	Format
PMC4417419.pdf		2.47 MB	Adobe PDF	View/Open